Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CL-387785
i
Other names:
WAY-EKI 785, CL-387785, EKI-785, CL 387785
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(5)
News
Trials
Company:
Pfizer
Drug class:
EGFR inhibitor
Related drugs:
‹
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
MCLA-129 (3)
necitumumab (3)
befotertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
AZD3759 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
TY-9591 (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
MCLA-129 (3)
necitumumab (3)
befotertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
AZD3759 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
TY-9591 (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
›
Associations
(5)
News
Trials
Filter by
Latest
over1year
Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic glycolysis and the growth of bladder cancer cells via regulation of the EGFR/PI3K/AKT pathway. (PubMed, Int J Oncol)
Exo‑si‑PYCR1 blocked xenograft tumor growth and had good biocompatibility. Briefly, PYCR1 knocking loaded by BMSC‑derived Exos suppressed aerobic glycolysis and BC growth via the PI3K/AKT pathway by binding to EGFR.
over 1 year ago
Journal
|
PRO-C3 (Pyrroline-5-carboxylate reductase)
|
CL-387785
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login